Semaglutide
GLP-1 Receptor Agonist
Also known as: Wegovy (weight management), Ozempic (diabetes), Rybelsus (oral)
Last updated May 8, 2026
What is Semaglutide?
Everyone’s talking about Ozempic — but every piece of information you find is coming from someone who profits when you start a prescription. Here’s the independent assessment.
Semaglutide is a synthetic GLP-1 receptor agonist. Your gut naturally produces GLP-1 after eating — it tells your brain you’re full, slows stomach emptying and regulates blood sugar. Semaglutide mimics this but lasts a week instead of minutes, which is why it’s dosed weekly. Manufactured by Novo Nordisk as Wegovy (weight), Ozempic (diabetes) and Rybelsus (oral). This is a fully FDA-approved pharmaceutical, not a compounded peptide.
What Does the Research Actually Show?
STEP 1 trial (1,961 participants) showed 14.9% weight reduction vs 2.4% placebo. STEP UP trial at higher 7.2mg dose achieved ~21% loss. Oral 25mg formulation achieved 16.6% loss.
SELECT trial (17,604 participants, 41 countries) showed 20% reduction in heart attack, stroke and cardiovascular death.
Extensive SUSTAIN and PIONEER trial programs with significant HbA1c reduction.
Active investigation in kidney disease, liver disease, addiction, Alzheimer’s and sleep apnea.
How Is Semaglutide Administered?
| Route | Weekly subcutaneous injection or daily oral tablet |
| Frequency | Once weekly (injectable) or daily (oral) |
| Dose escalation | Injectable starts at 0.25mg weekly, escalates over ~16 weeks to 2.4mg maintenance per FDA-approved protocol |
| Access | Prescribed by licensed providers; FDA-approved formulations (Wegovy, Ozempic, Rybelsus) only at retail pharmacies |
For a guide to injection supplies and self-administration basics, see our Injectable Peptide Supplies Guide →
What Are the Side Effects and Risks?
- GI effects (nausea, vomiting, diarrhea, constipation) — most common, usually during escalation.
- Muscle loss — research shows meaningful lean mass reduction, especially in women and older adults. Resistance training and protein intake are important.
- Pancreatitis — rare but reported.
- Thyroid concerns — boxed warning, contraindicated with medullary thyroid carcinoma history or MEN 2.
- Gallbladder issues — increased gallstone risk.
- Weight regain — STEP 4 trial showed significant regain after discontinuation.
See our independent week-by-week guide to what to expect on semaglutide, including side effects the clinical trials missed Read the semaglutide timeline →
Who Should NOT Use Semaglutide?
If you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): This is a boxed warning — the FDA’s most serious category. Animal studies showed thyroid C-cell tumors. This is not a theoretical hedge. It is a hard contraindication.
If you have a history of pancreatitis: Rare cases of acute pancreatitis have been reported in clinical trials and post-marketing surveillance. If you’ve had pancreatitis before, the risk-benefit calculation changes significantly. Your provider needs to weigh this explicitly.
If you have a history of gallbladder disease: Semaglutide increases the risk of gallstones and cholecystitis, likely driven by rapid weight loss. If you’ve had gallbladder issues — or have already had your gallbladder removed — discuss this with your provider before starting.
If you are pregnant, planning to become pregnant or breastfeeding: Semaglutide is contraindicated in pregnancy. The FDA recommends discontinuing at least 2 months before a planned pregnancy due to the drug’s long half-life. There is no safety data in breastfeeding.
If you have a history of eating disorders: Semaglutide dramatically reduces appetite and can alter your relationship with food. For someone with a history of anorexia or restrictive eating patterns, this appetite suppression can reinforce disordered behaviors. A provider who understands both metabolic health and eating disorder history should be involved — not just someone who will write the prescription.
If you have diabetic retinopathy: The SUSTAIN-6 trial showed an increased rate of retinopathy complications in patients with type 2 diabetes using semaglutide. If you have existing diabetic retinopathy, your ophthalmologist and prescriber both need to be aware.
If you are using compounded semaglutide from any source: As of 2026, there is no legitimate compounded semaglutide available. The FDA has issued dozens of warning letters to compounders and telehealth companies. If your semaglutide is not brand-name Ozempic, Wegovy or Rybelsus from a licensed retail pharmacy, you are taking an unregulated product with no quality assurance. This isn’t a gray area — it’s a red flag.
If your BMI doesn’t meet prescribing criteria and you’re seeking it for cosmetic weight loss: Semaglutide is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity. Using it below these thresholds means you’re outside the studied population, insurance is unlikely to cover off-label use and the risk-benefit ratio hasn’t been established for your situation. The muscle loss concern is especially relevant for people who are not clinically overweight.
Before You Start: Get Baseline Labs
Standard baseline workup for any GLP-1 receptor agonist applies to semaglutide. Your provider should establish baseline values before starting so they have something to track response and complications against.
Baseline workup before starting:
- HbA1c, fasting glucose — primary efficacy markers and screening for undiagnosed Type 2 diabetes
- Lipid panel — semaglutide tends to improve lipid profiles; baseline gives a reference point
- Comprehensive metabolic panel (CMP) — kidney function (creatinine, eGFR), electrolytes, liver enzymes
- TSH, free T4 — if you have thyroid symptoms or family history
- Lipase — pancreatitis risk is elevated on GLP-1s; a baseline reading gives reference if abdominal symptoms develop later
If your provider isn’t recommending baseline labs, that’s worth questioning — this is standard of care for any FDA-approved GLP-1 prescribing.
For ongoing monitoring once you’re on semaglutide, see our What to Expect on Semaglutide guide.
Order at-home labs from Everlywell →Lab recommendations are the same regardless of which service you use.
- 1Am I a good candidate for semaglutide based on my BMI, health history and goals? Are there contraindications I should know about?
- 2Which formulation do you recommend — injectable or oral? What’s the rationale?
- 3What does long-term maintenance look like? What happens if I stop the medication?
- 4What is the prescription pathway for the FDA-approved formulations, and what manufacturer access programs exist?
- 5Are you prescribing FDA-approved semaglutide, or a compounded version? (If compounded, understand that this carries regulatory and quality risk.)
Already on semaglutide? See our week-by-week guide for phase-specific questions and what to expect Open the semaglutide timeline →
Is Semaglutide Legal in 2026?
Semaglutide is FDA-approved and available through standard prescriptions at licensed pharmacies. As of April 2026, broad compounding is effectively prohibited. The FDA removed semaglutide from its drug shortage list in February 2025 and enforcement discretion has ended. On April 1, 2026, the FDA issued further clarification and confirmed DOJ involvement in enforcement.
On April 30, 2026, the FDA proposed excluding semaglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound it from bulk drug substances. The agency clarified that supply issues, convenience and cost aren't part of the clinical-need analysis. If finalized, this would close the remaining 503B pathway for compounded semaglutide entirely. Public comment runs through June 29, 2026.
The only remaining pathway for compounded semaglutide is a narrow patient-specific exception under 503A when a prescriber documents the FDA-approved product cannot be used for that specific patient. No generic versions of semaglutide are expected until the early 2030s.
How Do I Get Semaglutide Through a Legitimate Provider?
These providers meet our evaluation criteria: verified medical license, labs required before prescribing, and medications sourced from licensed U.S. pharmacies.
Peter MD
Hormone optimization, peptides, and longevity. Labs required before prescribing.
Not available in ID, AL. Lab work not available in NY, NJ, RI.
Book a ConsultationEnhance MD
Physician-led metabolic wellness. Comprehensive labs and ongoing provider monitoring included.
Not available in AL, AR, GA, HI, LA, MS, MO, ND, SC, TN, WV.
Book a ConsultationWe continuously evaluate providers. New additions will appear here as they’re verified.
These are affiliate links. We may earn a commission if you book through them. This never influences our evidence ratings or recommendations.